Company: INMB
Filing Date: 2025-10-14
Form Type: DEF 14A
Source: 0001213900-25-098715
Chunk: 14

Company: Inmune Bio, Inc.
Filing Date: 2025-10-14
Form: DEF 14A
Chunk 14
---
 available to the Company, unless the participant disposes of the shares within (i) two years after the date of grant of the option or (ii) within one year of the date the shares were transferred to the participant. If the shares are sold or otherwise disposed of before the end

9 of the one -yearand two -yearperiods specified above, the difference between the option exercise price and the fair market value of the shares on the date of the option’s exercise (or the date of sale, if less) will be taxed at ordinary income rates, and the Company will be entitled to a deduction to the extent that the participant recognizes ordinary income. Non-Qualified Stock Options The grant or repricing of a non -qualifiedstock option under the Plans is not expected to result in any federal income tax consequences to the participant or to the Company. Generally, upon exercise of a non -qualifiedstock option, the participant will realize ordinary income, and the Company will be entitled to a tax deduction, in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. Tax Effect for the Company We generally will be entitled to a tax deduction in connection with the Option Repricing in an amount equal to the ordinary income realized by the holder at the time the holder recognizes such income (for example, the exercise of a non -qualifiedstock option). We will generally not be entitled to a tax deduction in the case of an ISO for which there is a qualifying disposition following exercise. Special rules limit the deductibility of compensation paid to our Chief Executive Officer and other “covered employees” within the meaning of Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”). Under Code Section 162(m), the annual compensation paid to any of these specified service providers will be deductible only to the extent that it does not exceed $1,000,000. Financial Statements Our financial statements and other information required by Item 13(a) are incorporated by reference from our Annual Report on Form 10 -Kfor the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025. Required Vote of Stockholders The approval of Proposal 1 requires the affirmative vote of a majority of the votes properly cast at the Special Meeting for such matter. You may vote “for,” “against” or “abstain” with respect to Proposal 1. Abstentions and broker non -votes, if any